Today's the day for Pegylated stuff announcements....
8:31AM Schering-Plough: Retreatment with PEG-INTRON and REBETOL combination therapy can result in sustained virologic response (SGP) 22.78 : Co reported data from EPIC3, a large ongoing clinical study, showing that retreatment with PEG-INTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy can result in sustained virologic response in patients with chronic hepatitis C who failed previous treatment with any alpha interferon-based combination therapy, including peginterferon regimens. In this study, 56% of patients who had undetectable virus after 12 weeks went on to achieve S.V.R. with a 48-week course of therapy. Of the first 1,354 patients retreated, approx 38% had undetectable virus at week 12. Importantly, patients who did not have undetectable virus at 12 weeks had little chance of achieving S.V.R. Overall, 23% of patients achieved S.V.R. The primary end point of the study was S.V.R., defined as undetectable plasma HCV-RNA 24 weeks after the end of treatment. An aim of the study was to further characterize early viral response at week 12 as a predictor of S.V.R. in these patients.
+++++++++++++++++++++++++++++++
9:01AM Idenix Pharma: 200 mg/day of valopicitabine, combined with pegylated interferon, resulted in favorable viral suppression (IDIX) 9.88 : Co announces interim results of the phase IIb clinical trial of its hepatitis C investigational therapy, valopicitabine, dosed in combination with pegylated interferon. In this study, 200 mg/day of valopicitabine, combined with pegylated interferon, resulted in favorable viral suppression with a low rate of side effects in treatment naive patients with genotype-1 HCV infection after 24 weeks of treatment. The results will be presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, Massachusetts.
====================================== |
